We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.
- Authors
van den Bent, M J; Chinot, O; Boogerd, W; Bravo Marques, J; Taphoorn, M J B; Kros, J M; van der Rijt, C C D; Vecht, C J; De Beule, N; Baron, B
- Abstract
Oligodendroglial tumors are chemosensitive, with two-thirds of patients responding to PCV combination chemotherapy with procarbazine, lomustine (CCNU) and vincristine. Temozolomide (TMZ), a new alkylating and methylating agent has shown high response rates in recurrent anaplastic astrocytoma. We investigated this drug in recurrent oligodendroglial tumors (OD) and mixed oligoastrocytomas (OA) after prior PCV chemotherapy and radiation therapy.
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Vol 14, Issue 4, p599
- ISSN
0923-7534
- Publication type
Journal Article
- DOI
10.1093/annonc/mdg157